The Rudd Report, Dated April 18, 2008, Updates AMDL's Recent Achievements
April 25 2008 - 3:29PM
PR Newswire (US)
TUSTIN, Calif., April 25 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), an international biopharma company with development and
manufacture of proprietary pharmaceutical and diagnostic products
in China, announced today that a 4th Quarter Update and Year End
Report on AMDL has been posted by analyst Lauren Rudd at
(http://www.ruddreport.com/). It includes a 12 month target price
of $23 and a Buy Recommendation. The Report highlights AMDL's
recent and anticipated company goals and objectives in regards to
DR-70(TM), Human Papilloma Virus (HPV), Jade Pharmaceutical Inc.
2008 business expansion and JPGreen Health & Beauty Clinics. It
also covers various Peer Group Comparison & Valuation Analysis
and their views and opinions on financial performance for FY2008.
The 21-page report goes into significant detail about AMDL's
products, particularly AMDL's recent announcement in April 2008
that it has entered into an exclusive sublicense agreement for a
diagnostic product for in-vitro genotype testing in women with
Human Papilloma Virus (HPV), a potential billion dollar market.
"AMDL has had another profitable quarter, making it two in a row, a
trend we feel goes a long way towards reaffirming our current
projections that by the end of 2008, revenues from Jade alone will
reach or exceed $38 million," Mr. Rudd writes. About Jade
Pharmaceutical Inc.: Jade has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiary, Jade currently manufactures large volume
injectable fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures 107 generic, over
the counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be
obtained at http://www.amdl.com/. Forward-Looking Statements: This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Disclaimer by Rudd This disclaimer is an integral part of Rudd's
service. Please read it before investing in any security on which
we report. Opinions are solely those of the staff of The Rudd
Report and are subject to change without notice. Our reports are
for information only and we do not offer securities or solicit the
offer of securities of any company. Our reports are to inform the
public and not to promote any company or its securities. We do not
inform any company in advance of the nature or conclusions of our
reports nor can a company change what we write. In the case of AMDL
we received a fee for coverage of the current quarter in the amount
of $6,000. Our reports contain factual statements and opinions. We
derive these factual statements from sources that we believe are
accurate. However, we do not represent that the facts presented are
accurate or complete. Furthermore, the information contained in
this report may become inaccurate because of the passage of time
and should therefore be read for historical information only.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: Paul Knopick, AMDL Investor Relations, +1-949-707-5365,
Voice Mail, +1-714-505-4460 Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024